¿Dermopatía fibrosante nefrogénica o fibrosis sistémica nefrogénica? ¿Qué es lo que sabemos y qué debemos aprender?

Translated title of the contribution: Nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis? What we know and what we have to learn

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Nephrogenic systemic fibrosis (NSF) was first recognized as a unique entity in 1997 and subsequently defined in the literature in 2000 as a novel fibrosing disorder occurring in the setting of renal disease. Prevention, early recognition and treatment are essential to limiting its impact. The most important risk factors for developing NSF are chronic or significant acute kidney disease (especially dialysis dependent patients) and the administration of gadolinium (GD3) containing contrast agents, agents that cause NSF by releasing free gadolinium (GD3) into tissues based on their pharmacokinetics. International commissions in drug control and medicinal products recommend to avoid gadolinium based contrast agents in patients with GFR <30ml/minute/1.73m 2. Unfortunately there is lack of universally effective therapy at this time and the literature is based on case reports and small case series. Recommendations to guide the use of gadolinium based contrast agents in patients with underlying kidney disease should be individualized and considered in consultation with the ordering physician, radiologist and nephrologist.

Original languageSpanish
Pages (from-to)109-117
Number of pages9
JournalNefrologia
Volume29
Issue number2
DOIs
StatePublished - Jul 24 2009

Fingerprint

Nephrogenic Fibrosing Dermopathy
Gadolinium
Contrast Media
Kidney Diseases
Drug and Narcotic Control
Acute Disease
Dialysis
Referral and Consultation
Pharmacokinetics
Physicians
Kidney
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

¿Dermopatía fibrosante nefrogénica o fibrosis sistémica nefrogénica? ¿Qué es lo que sabemos y qué debemos aprender? / Ortega, L. M.; Contreras, Gabriel; Lenz, Oliver.

In: Nefrologia, Vol. 29, No. 2, 24.07.2009, p. 109-117.

Research output: Contribution to journalArticle

@article{b380c6a8467f4d278480d00b21babee2,
title = "¿Dermopat{\'i}a fibrosante nefrog{\'e}nica o fibrosis sist{\'e}mica nefrog{\'e}nica? ¿Qu{\'e} es lo que sabemos y qu{\'e} debemos aprender?",
abstract = "Nephrogenic systemic fibrosis (NSF) was first recognized as a unique entity in 1997 and subsequently defined in the literature in 2000 as a novel fibrosing disorder occurring in the setting of renal disease. Prevention, early recognition and treatment are essential to limiting its impact. The most important risk factors for developing NSF are chronic or significant acute kidney disease (especially dialysis dependent patients) and the administration of gadolinium (GD3) containing contrast agents, agents that cause NSF by releasing free gadolinium (GD3) into tissues based on their pharmacokinetics. International commissions in drug control and medicinal products recommend to avoid gadolinium based contrast agents in patients with GFR <30ml/minute/1.73m 2. Unfortunately there is lack of universally effective therapy at this time and the literature is based on case reports and small case series. Recommendations to guide the use of gadolinium based contrast agents in patients with underlying kidney disease should be individualized and considered in consultation with the ordering physician, radiologist and nephrologist.",
author = "Ortega, {L. M.} and Gabriel Contreras and Oliver Lenz",
year = "2009",
month = "7",
day = "24",
doi = "10.3265/NEFROLOGIA.2009.29.2.4842.EN.FULL",
language = "Spanish",
volume = "29",
pages = "109--117",
journal = "Nefrologia",
issn = "0211-6995",
publisher = "Grupo Aula Medica S.A.",
number = "2",

}

TY - JOUR

T1 - ¿Dermopatía fibrosante nefrogénica o fibrosis sistémica nefrogénica? ¿Qué es lo que sabemos y qué debemos aprender?

AU - Ortega, L. M.

AU - Contreras, Gabriel

AU - Lenz, Oliver

PY - 2009/7/24

Y1 - 2009/7/24

N2 - Nephrogenic systemic fibrosis (NSF) was first recognized as a unique entity in 1997 and subsequently defined in the literature in 2000 as a novel fibrosing disorder occurring in the setting of renal disease. Prevention, early recognition and treatment are essential to limiting its impact. The most important risk factors for developing NSF are chronic or significant acute kidney disease (especially dialysis dependent patients) and the administration of gadolinium (GD3) containing contrast agents, agents that cause NSF by releasing free gadolinium (GD3) into tissues based on their pharmacokinetics. International commissions in drug control and medicinal products recommend to avoid gadolinium based contrast agents in patients with GFR <30ml/minute/1.73m 2. Unfortunately there is lack of universally effective therapy at this time and the literature is based on case reports and small case series. Recommendations to guide the use of gadolinium based contrast agents in patients with underlying kidney disease should be individualized and considered in consultation with the ordering physician, radiologist and nephrologist.

AB - Nephrogenic systemic fibrosis (NSF) was first recognized as a unique entity in 1997 and subsequently defined in the literature in 2000 as a novel fibrosing disorder occurring in the setting of renal disease. Prevention, early recognition and treatment are essential to limiting its impact. The most important risk factors for developing NSF are chronic or significant acute kidney disease (especially dialysis dependent patients) and the administration of gadolinium (GD3) containing contrast agents, agents that cause NSF by releasing free gadolinium (GD3) into tissues based on their pharmacokinetics. International commissions in drug control and medicinal products recommend to avoid gadolinium based contrast agents in patients with GFR <30ml/minute/1.73m 2. Unfortunately there is lack of universally effective therapy at this time and the literature is based on case reports and small case series. Recommendations to guide the use of gadolinium based contrast agents in patients with underlying kidney disease should be individualized and considered in consultation with the ordering physician, radiologist and nephrologist.

UR - http://www.scopus.com/inward/record.url?scp=67650707615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650707615&partnerID=8YFLogxK

U2 - 10.3265/NEFROLOGIA.2009.29.2.4842.EN.FULL

DO - 10.3265/NEFROLOGIA.2009.29.2.4842.EN.FULL

M3 - Article

VL - 29

SP - 109

EP - 117

JO - Nefrologia

JF - Nefrologia

SN - 0211-6995

IS - 2

ER -